XML 38 R29.htm IDEA: XBRL DOCUMENT

Shareholders' Equity (Tables)

3 Months Ended

Mar. 31, 2021

Equity [Abstract]

Schedule of Components of Shareholder's Equity

The following tables show changes in components of shareholders’ equity for the three months ended March 31, 2021 (unaudited and in thousands).

		Common Stock								Accumulated Other Comprehensive				Accumulated				Total Shareholders’
		Shares				Amount				Loss				Deficit				Equity
BALANCE AT JANUARY 1, 2021			69,117			$	157,160			$	-			$	(123,677)			$	33,483
Net loss			-				-				-				(3,919)				(3,919)
Stock-based compensation			-				1,290				-				-				1,290
Sale of common shares, including at-the-market transactions			18,427				71,746				-				-				71,746
Financing costs paid to issue common shares, including at-the-market transactions			-				(2,878)				-				-				(2,878)
Exercise of stock options			140				348				-				-				348
Exercise of warrants			248				802				-				-				802
Issuance of common stock to Razor Genomics			982				5,756				-				-				5,756
BALANCE AT MARCH 31, 2021			88,914			$	234,224			$	-			$	(127,596)			$	106,628

The following table shows changes in components of shareholders’ equity for the three months ended March 31, 2020 (unaudited and in thousands).

		Common Stock								Accumulated Other Comprehensive				Accumulated				Total Shareholders’
		Shares				Amount				Loss				Deficit				Equity
BALANCE AT JANUARY 1, 2020			57,032			$	124,583			$	-			$	(93,745)			$	30,838
Net loss			-				-				-				(7,732)				(7,732)
Stock-based compensation			-				937				-				-				937
Sale of common shares			3,523				7,597				-				-				7,597
Financing costs paid to issue common shares			-				(1)				-				-				(1)
Shares issued upon vesting of RSU, net of shares retired to pay employees’ taxes			13				(14)				-				-				(14)
Issuance of common stock for Insight Genetics acquisition			1,916				5,000				-				-				5,000
BALANCE AT MARCH 31, 2020			62,484			$	138,102			$	-			$	(101,477)			$	36,625